

## Q-linea expands the Gram-negative panel

Q-linea today announces that the company has finished the clinical trials for the drug Meropenem-Vaborbactam with strong results and is therefore able to claim IVDR compliance and add the drug to the existing BC-GN panel. The company expects commercial availability in Europe during Q2 2024.

Meropenem-Vaborbactam is a combination drug of a Carbapenem and a beta-lactamase inhibitor with enhanced activity against gram-negative organisms, particularly Enterobacterales with class A and C carbapenemases. Tiziana Di Martino, Chief Medical Officer at Q-linea commented: "Meropenem-Vaborbactam is a very interesting drug which can help to treat critically ill patients, especially when certain resistance mechanisms are present. We had many customer interactions where this antibiotic has been raised as a strong wish to be included on the panel and are very glad to be able to add it on. One of the strengths of ASTar is the capacity of 336 wells we are having on our disk, and this enables us to add this new drug without compromising on any previously present antibiotic or dilution range, so it is true added value for our customers and their patients."

"This is an important step in our continuous strive to offer the best product for our customers. The use of antibiotic combinations has become increasingly important for treatment and Meropenem-Vaborbactam is another important addition to our panel to fight resistant bacteria. We believe that the addition will be well received by our customers helping them providing the best possible treatment for patients with blood stream infections," said Jonas Jarvius, CEO and President at Q-linea.

### For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

[Jonas.Jarvius@qlinea.com](mailto:Jonas.Jarvius@qlinea.com)

+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB

[Christer.Samuelsson@qlinea.com](mailto:Christer.Samuelsson@qlinea.com)

+46 (0) 70-600 15 20

### About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).

**Attachments**

Q-linea expands the Gram-negative panel